Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. - Wikidata - awgldk - TriplyDB

Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance.

Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance.

http://www.wikidata.org/entity/Q37252459

about

HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors Interaction between Tat and Drugs of Abuse during HIV-1 Infection and Central Nervous System Disease Chronic inflammation and the role for cofactors (hepatitis C, drug abuse, antiretroviral drug toxicity, aging) in HAND persistence Role of neuroimaging in HIV-associated neurocognitive disorders Genetic, transcriptomic, and epigenetic studies of HIV-associated neurocognitive disorder Neurologic complications of HIV-1 infection and its treatment in the era of antiretroviral therapy Pharmacokinetic, Pharmacogenetic, and Other Factors Influencing CNS Penetration of Antiretrovirals The NRTIs lamivudine, stavudine and zidovudine have reduced HIV-1 inhibitory activity in astrocytes Neurocognitive impairment in patients treated with protease inhibitor monotherapy or triple drug antiretroviral therapy Computational modeling reveals distinct effects of HIV and history of drug use on decision-making processes in women Systems analysis of human brain gene expression: mechanisms for HIV-associated neurocognitive impairment and common pathways with Alzheimer's disease Clinical Trials in Neurovirology: Successes, Challenges, and Pitfalls Getting to 90-90-90 in paediatric HIV: What is needed?Neurotoxic effects of AZT on developing and adult neurogenesis Neuroimaging of HIV-associated neurocognitive disorders (HAND)PET brain imaging in HIV-associated neurocognitive disorders (HAND) in the era of combination antiretroviral therapy.Neurologic presentations of AIDS.Brain dysfunction in the era of combination antiretroviral therapy: implications for the treatment of the aging population of HIV-infected individuals HIV-1 neuroimmunity in the era of antiretroviral therapy.Pathogenesis of HIV in the central nervous system HIV protease inhibitor exposure predicts cerebral small vessel disease.Changes in PINCH levels in the CSF of HIV+ individuals correlate with hpTau and CD4 count.The cerebrospinal fluid HIV risk score for assessing central nervous system activity in persons with HIV.HIV-associated neurocognitive disorder.Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions Host genetic factors predisposing to HIV-associated neurocognitive disorder.Proteinuria is associated with neurocognitive impairment in antiretroviral therapy treated HIV-infected individuals Central nervous system antiretroviral efficacy in HIV infection: a qualitative and quantitative review and implications for future research.Neuropsychological outcomes in adults commencing highly active anti-retroviral treatment in South Africa: a prospective study.Total raltegravir concentrations in cerebrospinal fluid exceed the 50-percent inhibitory concentration for wild-type HIV-1.HIV, dementia and antiretroviral drugs: 30 years of an epidemic.Antiretroviral therapy CNS penetration and HIV-1-associated CNS disease HIV-associated neurocognitive disorders: perspective on management strategies Impact of antiretroviral therapy on HIV-related brain injury.Subcortical brain atrophy persists even in HAART-regulated HIV disease.Virological efficacy in cerebrospinal fluid and neurocognitive status in patients with long-term monotherapy based on lopinavir/ritonavir: an exploratory study.Persistence of HIV-associated cognitive impairment, inflammation, and neuronal injury in era of highly active antiretroviral treatment Early viral suppression improves neurocognitive outcomes in HIV-infected children.Role of the immune system in HIV-associated neuroinflammation and neurocognitive implications.Antiretroviral therapy reduces neurodegeneration in HIV infection

P2860

Q24631745-46CCB066-C036-42A6-8D8D-E15ACB87E92F Q26770397-2E0FD97A-87F0-42C7-83EA-5DB361BF984B Q26825762-ADBA0E87-42C7-48B9-B171-E839D6185154 Q26852705-FAB0C1A8-9D08-4D69-9591-173BA6098CCC Q26865707-74A1B20F-3887-487E-9AC9-BBFA310543DC Q27000422-7B5FF70F-186B-44EB-81A5-996D46DB0B0A Q28069383-A8A3B292-D1EE-4846-879F-E872DAB16803 Q28486204-4C855253-E547-4B5D-B300-D21D4D365A18 Q28534903-ACD0478C-4F45-4906-9CAA-22F92A41701B Q28535185-96BD3EC2-00B4-417B-9143-87C7FE1B3880 Q28709047-69EC95A5-D817-4759-9147-DEEE5EC820BB Q30250271-D4D5F2E1-2A40-4AE7-8504-1452695F9FCA Q30385352-A2113B1F-6A06-4503-93E5-E3F36E7463AA Q30414740-A6800665-513D-43C8-991E-6E938CF53B9B Q30854917-EE049BAF-2E09-486A-BF78-4F7FF3A14BF3 Q31153188-4470B094-4E0D-44FC-BF01-6386B34BF4E6 Q33590337-63E91D2E-7D96-40A6-B2F2-612A64E32B0F Q33614467-C630E5B7-B3B8-43F4-B5E6-859670BA494A Q33733529-2A771696-685B-4A85-B24B-6DAF89E47F9A Q33781978-E8AB957A-A2A2-4F08-8A3D-1B0E6394CEB7 Q33807507-4D55F053-3DE4-4A9A-AFE7-326CF9118564 Q33924678-851B8B8F-7F2E-4502-A3D2-0EDB0F18581D Q33938797-97B8A6E4-FE47-4F7B-9ED1-3D9986E4EBD5 Q33939729-5ACE6662-A839-49CA-9DE4-2B8D7C6AB326 Q33980117-1214D3C9-D788-4082-9AC9-B9E71D37607F Q34001122-BBB2D645-A6A7-470C-8FA2-E3409492DC8C Q34048920-47939997-CF1E-48B3-B595-08088F105F26 Q34080236-31C31199-EF26-4B8D-B4BB-CA3B2955FA28 Q34159453-35743483-A8B6-45EF-A747-6AD19FFAE583 Q34309626-E09BD42F-9A8F-48BA-8101-EE1D51FE6483 Q34573511-6A29249D-00BD-449C-BE47-F434B2686858 Q34647014-502E6D4A-A326-448A-999F-4F4C455AB12B Q34652590-6846D2FE-6161-493B-8FB6-4ABA119EB01D Q34699119-7A7FCBC6-811B-4A0B-9E3B-A0F02773484C Q34862412-A30EAC76-5068-4A99-9376-89D82C0E5754 Q34906495-70900C85-59B6-4B72-9D9F-E00BFBBA4CA4 Q35078313-D2D9FDF1-8177-46EE-8EFD-1F03ED4B715D Q35095168-199427DC-D22E-4BB6-B9AD-FE02FD8B8ADF Q35125996-7B288A35-898A-45EE-A0C4-7A1C56A8F181 Q35159221-F296F8A8-30B1-416B-B21A-6EA33B9508AC

P2860

Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance.

http://www.wikidata.org/entity/Q37252459

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on July 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Impact of combination antiretr ...... nd neurocognitive performance.

@en

Impact of combination antiretr ...... nd neurocognitive performance.

@nl

type

label

Impact of combination antiretr ...... nd neurocognitive performance.

@en

Impact of combination antiretr ...... nd neurocognitive performance.

@nl

prefLabel

Impact of combination antiretr ...... nd neurocognitive performance.

@en

Impact of combination antiretr ...... nd neurocognitive performance.

@nl

P1433

Q37252459-882E914B-6E98-4BB4-9EC4-3034498E67DA

P1476

Q37252459-8BC90054-B029-4767-B18F-5C0ED086E347

P2093

Q37252459-2B64DB67-5F6C-4B72-989A-58E4698A054D

Q37252459-419A286F-D80F-484F-8F7F-57D2532FCE15

Q37252459-4B7C4DC0-48F6-4FA8-8DF7-7A2EF2C39E78

Q37252459-5D24BF77-851B-4A04-A442-F9532137CE2C

Q37252459-70200035-6B8F-496B-B71E-E97A40A72A28

Q37252459-82C09E39-3BD8-4AAD-ACB0-778023A57D9D

Q37252459-AB2E1ABA-D22A-44E5-844E-A48F9AC5F098

Q37252459-AE7BA977-6F42-4DB6-9176-42C88C492410

Q37252459-BCD797F8-FFF3-4226-934F-4302BCC041D4

Q37252459-E652335A-3D9C-476A-A130-8D0DA8A17CE8

P2860

Q37252459-05A1C9D7-2853-4729-9B5E-CD81ECD4E392

Q37252459-0F63B4FF-96D6-4068-8AFB-EFA96C85252E

Q37252459-1E3CF476-2D29-4958-B493-9986CA7DEA29

Q37252459-1F55AC3D-92A6-4514-BB2D-CDC90EE569E8

Q37252459-54C8DCAA-5C36-410D-BE87-392DA3EEF95E

Q37252459-69E1CBB3-277B-439F-890B-C749F8568ECD

Q37252459-72FC6707-AB5B-4F02-8167-DEABFE6EDA84

Q37252459-7398B74E-4D9F-4A39-86EE-A8C747EED77C

Q37252459-81938C9E-A73E-4BBB-A9B6-F689FDAEBCDE

Q37252459-86B56D4A-8A7F-42A5-A425-53A0DF3D7B18

P304

Q37252459-08517899-3DE2-479B-9FF7-9368344E8941

P31

Q37252459-84B115D1-5C73-4F26-A35B-969E489B4DDE

P356

Q37252459-327E0EC7-E907-4F00-8A48-0C97DFF31A50

P407

Q37252459-FEF75F18-4C3E-4452-9D36-9655EE50A31D

P433

Q37252459-4174A127-6C87-4DE3-8737-F0E4ECADC566

P478

Q37252459-E7E09B90-2224-4019-A158-B7F939F1C642

P50

Q37252459-4B58F0E1-C7AA-4E97-831C-C671949AB9EC

Q37252459-E3BF0492-2D87-49D4-8C5A-3FB3D28EA370

Q37252459-F9C7EF00-B99B-4540-931D-D36135DCC9A4

P577

Q37252459-84FBF168-5DA2-428D-AA3C-A84970885FA8

P698

Q37252459-28849758-2844-4BFA-A833-BE429A6F94A0

P921

Q37252459-7C2B07E1-F3E3-44B5-9CDF-B0D33199739E

Q37252459-D6382DA6-CCEB-4A67-B264-48453C579171

Q37252459-E93708FD-0FCF-498F-B1B0-ECFA8CC9976A

P932

Q37252459-0470BC3D-A09D-4D07-BDCD-0EBBB057EC7A

P356

QAD.0B013E32832C4152

P1433

P1476

Impact of combination antiretr ...... nd neurocognitive performance.

@en

P2093

AIDS Clinical Trials Group 736 Study Team

http://www.w3.org/2001/XMLSchema#string

Christina M Marra

http://www.w3.org/2001/XMLSchema#string

David B Clifford

http://www.w3.org/2001/XMLSchema#string

Giovanni Schifitto

http://www.w3.org/2001/XMLSchema#string

Justin C McArthur

http://www.w3.org/2001/XMLSchema#string

Katherine Henry

http://www.w3.org/2001/XMLSchema#string

Kevin Robertson

http://www.w3.org/2001/XMLSchema#string

Robert W Coombs

http://www.w3.org/2001/XMLSchema#string

Scott Evans

http://www.w3.org/2001/XMLSchema#string

Yu Zhao

http://www.w3.org/2001/XMLSchema#string

P2860

Determining the extent of cognitive change after coronary surgery: a review of statistical procedures.

Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system

Changing incidence of central nervous system diseases in the EuroSIDA cohort.

Neurological outcomes in late HIV infection: adverse impact of neurological impairment on survival and protective effect of antiviral therapy. AIDS Clinical Trial Group and Neurological AIDS Research Consortium study team.

Calculating correlation coefficients with repeated observations: Part 2--Correlation between subjects.

Changes in CSF and plasma HIV-1 RNA and cognition after starting potent antiretroviral therapy.

Factors influencing virological response to antiretroviral drugs in cerebrospinal fluid of advanced HIV-1-infected patients.

Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure.

Brain mitochondrial injury in human immunodeficiency virus-seropositive (HIV+) individuals taking nucleoside reverse transcriptase inhibitors.

Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders.

P304

1359-1366

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/QAD.0B013E32832C4152

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P50

Benigno Rodriguez

P577

2009-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19424052

http://www.w3.org/2001/XMLSchema#string

P921

cerebrospinal fluid

antiretroviral drug

P932

2706549

http://www.w3.org/2001/XMLSchema#string